Watson Pharmaceuticals Reports First Quarter 2009 Results; Raises 20...(18.8 18.8 Gain on asse...),Health

Date:4/30/2009

18.8 18.8 Gain on asset sales (1.5) (1.5) Loss on securities 1.1 1.1 Income taxes (17.5) (17.5) ----- ----- Adjusted net income 277.0 290.8 Add: Interest expense on CODES, net of tax 7.9 7.9 --- --- Adjusted net income, adjusted for interest on CODES $284.9 $298.7 ====== ====== Diluted earnings per share Diluted earnings per share - GAAP $2.15 $2.27 ===== ===== Diluted earnings per share - Adjusted $2.40 $2.52 ===== ===== Diluted weighted average common shares outstanding 118.6 118.6 ===== ===== The reconciliation table is based in part on management's estimate of net income for the year ending December 31, 2009. Watson expects certain known GAAP charges for 2009, as presented in the schedule above. Other GAAP charges that may be excluded from adjusted net income are possible, but their amounts are dependent on numerous factors that we currently cannot ascertain with sufficient certainty or are presently unknown. These GAAP charges, such as potential asset impairment charges, are dependent upon future events and valuations that have not yet been performed. The following table presents a reconciliation of forecasted net income for the 12 months ending Dec
'/>"/>

SOURCE Watson Pharmaceuticals, Inc. Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18
Related medicine news :

1. Watson Receives First FDA Approval for Manufacturing Product at Its Goa, India Facility
2. Watson Wyatt Identifies Major Benefit Trends During Open Enrollment Season
3. Texas Affiliates of Susan G. Komen for the Cure, Sen. Kirk Watson, Rep. Patrick Rose, Singer Kelly Willis, Breast Cancer Survivors and Activists Rally for Passage of Proposition 15
4. Watson Files FDA Application for Generic YAZ(R)
5. Watson Names Mark Durand Chief Financial Officer
6. Watson and Novartis Settle Lawsuit Over Exelon(R) Patent Litigation
7. Barr Subsidiary Sues Watson and Sandoz for SEASONALE(R) Patent Infringement
8. Watson Confirms Patent Litigation With Barr Related to Seasonale(R)
9. Watson Receives FDA Approval for Generic DuoNeb(R)
10. Watson to Distribute Alendronate Tablets
11. Medical Cost Increases to Accelerate Worldwide Over Next Five Years, Watson Wyatt Poll Finds